Closed Loop Acoustic Stimulation During Sedation With Dexmedetomidine (CLASS-D)

April 13, 2026 updated by: Ben J.A. Palanca, Washington University School of Medicine
Prospective within-subject study of dexmedetomidine sedation paired with CLAS conditions in repeated blocks. Intervention will consist of CLAS in-phase with EEG slow waves. Anti-phase stimulation will serve as an active control while sham stimulation will serve as a passive control.

Study Overview

Detailed Description

Both nonpharmacologic and pharmacologic interventions augment expression of EEG slow waves that mimic those of natural sleep. Closed loop auditory stimulation (CLAS) is a noninvasive inexpensive approach to augment the spectral power and duration of these slow waves. Whether in-phase CLAS may address this need is unknown, since acoustic potentiation of pharmacologically-induced slow waves has not been investigated. This prospective within-subject study of dexmedetomidine sedation paired with CLAS will assess the feasibility of augmenting EEG slow waves during sedation.

Study Type

Interventional

Enrollment (Actual)

18

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Missouri
      • St Louis, Missouri, United States, 63110
        • Washington University School of Medicine/Barnes-Jewish Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 40 years (Adult)

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Age 18-40 years
  • Healthy volunteers (American Society of Anesthesiologists Physical Status 1-2).

Exclusion Criteria:

  • Diagnosed sleep disorders
  • Habitually short sleepers
  • Diagnosed psychiatric disorders
  • Use of psychoactive medication (e.g., antidepressants, mood stabilizers or antipsychotics), diagnosed hearing disorder
  • Neck circumference > 40 cm
  • Body Mass Index > 30
  • Acknowledged recreational drug or nicotine use
  • Resting heart rate during slow wave sleep < 40 beats per minute
  • Pregnancy or nursing
  • Persistently inconsistent or elevated QST heat pain tolerance thresholds (>50 ºC).

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Diagnostic
  • Allocation: Non-Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: CLASS-D Cohort - In-phase
Within-subject crossover cohort with intervention, acoustic stimulation delivered in phase with the anticipated peak of EEG slow wave oscillation
A non-contrast brain MRI will be acquired for localizing EEG slow waves
Other Names:
  • Structural magnetic resonance imaging
Quantitative sensory testing (QST) using increasing ramp thermal stimulation (32-52 ºC) will be delivered to compare arousal thresholds between conditions.
Other Names:
  • Quantitative Sensory Testing
Unattended home sleep studies will be conducted on the night preceding sedation and on the night following sedation to assess changes in slow wave homeostasis.
Other Names:
  • Unattended polysomnography
All participants will receive dexmedetomidine with sedation titrated step-wise to 2, 3 or 4 ng/ml
Other Names:
  • Dexmedetomidine hydrochloride
All participants will be asked to perform the breathe-squeeze task throughout the experiment. This will allow us to determine loss and return of responsiveness.
Other Names:
  • Internally directed behavioral task
Acoustic stimulation (65 db) synchronized in-phase with the up-slope of EEG slow waves
Other Names:
  • In-phase CLAS with sensory testing
Active Comparator: CLASS-D Cohort - Anti-phase
Within-subject crossover cohort with intervention, acoustic stimulation delivered in phase with the anticipated trough of EEG slow wave oscillation
A non-contrast brain MRI will be acquired for localizing EEG slow waves
Other Names:
  • Structural magnetic resonance imaging
Quantitative sensory testing (QST) using increasing ramp thermal stimulation (32-52 ºC) will be delivered to compare arousal thresholds between conditions.
Other Names:
  • Quantitative Sensory Testing
Unattended home sleep studies will be conducted on the night preceding sedation and on the night following sedation to assess changes in slow wave homeostasis.
Other Names:
  • Unattended polysomnography
65 dB acoustic stimulation synchronized with the down-slope of the EEG slow waves (anti-phase)
Other Names:
  • Anti-phase CLAS with sensory testing
All participants will receive dexmedetomidine with sedation titrated step-wise to 2, 3 or 4 ng/ml
Other Names:
  • Dexmedetomidine hydrochloride
All participants will be asked to perform the breathe-squeeze task throughout the experiment. This will allow us to determine loss and return of responsiveness.
Other Names:
  • Internally directed behavioral task
Sham Comparator: CLASS-D Cohort - Sham
Within-subject crossover cohort with intervention, acoustic stimulation anticipated in phase with the anticipated peak of EEG slow wave oscillation but no acoustic stimulation delivered.
A non-contrast brain MRI will be acquired for localizing EEG slow waves
Other Names:
  • Structural magnetic resonance imaging
Quantitative sensory testing (QST) using increasing ramp thermal stimulation (32-52 ºC) will be delivered to compare arousal thresholds between conditions.
Other Names:
  • Quantitative Sensory Testing
Unattended home sleep studies will be conducted on the night preceding sedation and on the night following sedation to assess changes in slow wave homeostasis.
Other Names:
  • Unattended polysomnography
sham stimulation (0 dB volume)
Other Names:
  • Sham CLAS with sensory testing
All participants will receive dexmedetomidine with sedation titrated step-wise to 2, 3 or 4 ng/ml
Other Names:
  • Dexmedetomidine hydrochloride
All participants will be asked to perform the breathe-squeeze task throughout the experiment. This will allow us to determine loss and return of responsiveness.
Other Names:
  • Internally directed behavioral task

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Difference in EEG Slow Wave Activity From Sham to In-phase Stimulation
Time Frame: Sham stimulation and in-phase stimulation blocks during the intervention
EEG slow waves activity (power) relative to the timing of the stimulation. Values are log-transformed All participants serve in the same arm but experience both sham and in-phase blocks.
Sham stimulation and in-phase stimulation blocks during the intervention
Difference in EEG Slow Wave Activity From Anti-phase to In-phase Stimulation
Time Frame: Anti-phase and in-phase blocks during the intervention
EEG slow waves activity (power) relative to the timing of the stimulation. Values are log-transformed All participants serve in the same arm but experience both anti-phase and in-phase blocks.
Anti-phase and in-phase blocks during the intervention
Difference in EEG Slow Wave Density From Anti-phase to In-phase Stimulation
Time Frame: anti-phase and in-phase blocks during the intervention
Difference in EEG slow wave density from anti-phase to in-phase stimulation by looking at EEG slow waves duration relative to the timing of the stimulation All participants serve in the same arm but experience both anti-phase and in-phase blocks.
anti-phase and in-phase blocks during the intervention
Difference in EEG Slow Wave Density From Sham to In-phase Stimulation
Time Frame: Sham stimulation and in-phase stimulation blocks during the intervention
Difference in EEG slow wave density from sham to in-phase stimulation by looking at EEG slow waves relative to the timing of the stimulation All participants serve in the same arm but experience both sham and in-phase blocks.
Sham stimulation and in-phase stimulation blocks during the intervention

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Difference of Reactivity to Thermal Stimulation From Anti-phase to In-phase Stimulation
Time Frame: Anti-phase and in-phase blocks of the intervention
Difference of reactivity to thermal stimulation from anti-phase to in-phase stimulation by measuring the threshold for responsiveness to thermal stimulation All participants serve in the same arm but experience both anti-phase and in-phase blocks.
Anti-phase and in-phase blocks of the intervention
Difference of Reactivity to Thermal Stimulation From Sham to In-phase Stimulation
Time Frame: Sham and in-phase blocks during intervention
Difference of reactivity to thermal stimulation from sham to in-phase stimulation by measuring the threshold for responsiveness to thermal stimulation All participants serve in the same arm but experience both sham and in-phase blocks.
Sham and in-phase blocks during intervention
Slow Wave Activity Calculated During N3 Sleep
Time Frame: on the nights before and the night of the intervention
Change in slow wave activity on the night of the intervention will be compared to that on the night prior to the study session. Calculated as power
on the nights before and the night of the intervention

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Ben J Palanca, MD PhD, Washington University School of Medicine

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 20, 2021

Primary Completion (Actual)

June 1, 2022

Study Completion (Actual)

July 1, 2023

Study Registration Dates

First Submitted

December 9, 2019

First Submitted That Met QC Criteria

December 17, 2019

First Posted (Actual)

December 20, 2019

Study Record Updates

Last Update Posted (Actual)

May 1, 2026

Last Update Submitted That Met QC Criteria

April 13, 2026

Last Verified

April 1, 2026

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

Yes

product manufactured in and exported from the U.S.

Yes

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Sleep

Clinical Trials on MRI

Subscribe